Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that on September 10, 2026, the Compensation Committee of its Board of Directors granted inducement equity grants to 16 new employees, ...
Travere Therapeutics Inc. stock grades by Barron's. View TVTX fundamental and sentiment analysis powered by MarketGrader.
Pricing for ETFs is the latest price and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you ...
Travere Therapeutics was first featured on our site on August 14, 2024, when the stock was trading at $8.91. At the time, our ...
Complete Invesco Dorsey Wright Healthcare Momentum ETF funds overview by Barron's. View the PTH funds market news ...
Biotech leader Kiniksa stock is poised to hit a new buy point after shares soared 25% in response to better-than-expected ...
Investor's Business Daily on MSN
Travere Therapeutics outlook brightens as turnaround looms
Biotech name Travere Therapeutics is not profitable yet but a turnaround may be around the corner as the stock hovers near a buy zone.
The FDA’s Office of Prescription Drug Promotion sent Travere Therapeutics a letter over its advertising for Filspari, a drug that’s approved to slow kidney function decline in people with primary IgA ...
VegFest Kelowna returns to City Park in downtown Kelowna on Sunday, Sept. 20. It brings together local businesses, food ...
Excited to Join Travere Therapeutics as Director, Scientific Engagement and Professional Societies / AbbVie Oncology, Asud ...
Despite a wave of new therapies reshaping treatment across rare and glomerular kidney diseases, Alport syndrome has largely been left behind. Among kidney diseases evaluated by Spherix Global Insights ...
In this video from GlomCon Hawaii, Dana Rizk, MD, discusses highlights from a presentation concerning the design and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results